Melphalan
Myelodysplastic Syndrome With Excess Blasts
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 89/ 100
Competitive context
31 Active assets in the Myelodysplastic Syndrome With Excess Blasts cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytarabine University of Southern California | Phase 3 | BBB |
Fludarabine Fred Hutchinson Cancer Center | Phase 3 | BB |
Tacrolimus Fred Hutchinson Cancer Center | Phase 2 | BB |
Cyclosporin A Fred Hutchinson Cancer Center | Phase 2 | BB |
Etoposide M.D. Anderson Cancer Center | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Melphalan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →